Venture Capitalists Have A Growing Interest In Comparative Effectiveness
Executive SummaryVenture capitalists are taking a growing interest in the impact of comparative effectiveness research on future drug products and how results might affect products' ability to gain coverage by third-party payers
You may also be interested in...
Lack Of Cost-Effectiveness Analysis For Products In Development Could Affect Company Valuations, Attorney Mahinka Says
With payers playing a more prominent role in determining access to drugs, developers will need to focus more on the comparative value of a drug throughout the development cycle, including cost. That value equation also will become an important part of the M&A landscape, attorney Stephen Mahinka says.